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ABSTRACT: Background. The contemporary treatment of oropharyngeal
squamous cell carcinoma (SCC) is an area of debate. We report out-
comes of a minimally invasive approach involving transoral laser micro-
surgery (TLM).
Methods. A consecutive series of patients (n 5 153) undergoing primary
TLM for oropharyngeal SCC from 2006 to 2013 was studied. Human
papillomavirus (HPV) status was determined by p16 immunohistochem-
istry and high-risk HPV DNA in situ hybridization. Survival analyses were
evaluated using Kaplan–Meier statistics.
Results. Tumor subsites included tonsil (n 5 94; 61.5%), tongue base (n
5 38; 24.8%), and soft palate (n 5 21; 13.7%), with the majority being
American Joint Committee on Cancer (AJCC) stage III/IVa (n 5 124;
81.0%) and HPV-positive (n 5 101; 66.0%). Three-year overall survival
(OS), disease-specific survival (DSS), and disease-free survival (DFS)
were 84.5%, 91.7%, and 78.2%, respectively. HPV-positivity portended
favorable oncologic outcomes. One-year gastrostomy tube (G-tube)
dependency was 1.3%.
Conclusion. To the best of our knowledge, this is the largest single-
center TLM oropharyngeal SCC series to date. Our data suggest that
TLM 1/2 postoperative radiotherapy (PORT) results in at least as good
oncologic outcomes as chemoradiotherapy (CRT), while conferring swal-
lowing function advantages. VC 2016 Wiley Periodicals, Inc. Head Neck
00: 000–000, 2016
KEY WORDS: carcinoma, squamous cell/surgery, oropharyngeal
neoplasms/surgery, laser therapy/methods, oropharyngeal neo-
plasms/mortality, neoplasm recurrence, local, survival analysis
INTRODUCTION
Oropharyngeal squamous cell carcinoma (SCC) affecting
the tonsils, tongue base, and/or soft palate, is a rapidly
increasing disease in the United Kingdom and other
developed countries, presumed to be a result of Human
papillomavirus (HPV) infection; data suggest that, in
areas of Europe, up to 70% of oropharyngeal SCCs are
now HPV-associated.1–3 It is now widely accepted that
HPV-driven oropharyngeal SCC represents a separate dis-
ease entity with distinct tumor biology to that of HPV-
negative disease, with a propensity to affect younger
patients, often in the absence of conventional risk factors,
while conferring favorable survival.1,4–7 Indeed, HPV sta-
tus has been demonstrated to be a strong and independent
prognostic factor for survival, with HPV-positive oropha-
ryngeal SCC carrying a 58% reduction in the risk of
death compared to HPV-negative oropharyngeal SCC
(hazard ratio [HR], 0.42; 95% confidence interval [CI],
0.27–0.66).4
Despite the absence of level I evidence comparing sur-
gical and nonsurgical approaches in the management of
oropharyngeal SCC, cisplatin-based chemoradiotherapy
(CRT) is generally considered the current standard of
care for intermediate and advanced stage (American Joint
Committee on Cancer [AJCC] stage III/IVa) oropharyn-
geal SCC in the majority of centers in the United King-
dom, Northern Europe, and the United States.1,8 This
practice is largely predicated on the recognition of the
significant morbidity associated with open surgical
approaches and the enhanced survival noted with concur-
rent CRT over radiotherapy (RT) alone in the treatment
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of SCC of the head and neck (SCCHN) in general, and in
particular of the larynx and oropharynx.1,9–16 However,
the use of concurrent CRT or open surgery (involving
mandibulotomy and reconstruction) followed by adjuvant
RT for the treatment of oropharyngeal SCC results in sig-
nificant long-term dysphagia.11,15–25 Therefore, as the sur-
vival outcomes resulting from surgical and nonsurgical
strategies seem equitable, reducing the impact of treat-
ment on long-term function is key in patients with oro-
pharyngeal SCC, and in particular those with HPV-
positive disease who have a favorable prognosis and tend
to be younger and otherwise medically fit at presenta-
tion.4 Although treatment deintensification strategies in
the HPV-positive patient population have been advocated
— including reducing the total dose of radiation, addition
of biotherapy, omission of chemotherapy, and/or surgical
resection via a transoral approach2,9 — transoral surgery
added to conventional treatments (eg, CRT) has also been
advocated as a mechanism of intensifying treatment in
patients with poorer prognosis oropharyngeal SCC.1,26
Accordingly, transoral laser microsurgery (TLM) as part
of a deintensification strategy in HPV-positive oropharyn-
geal SCC is currently under investigation in the U.S.-
based Eastern Cooperative Oncology Group-3311
(NCT01898494) and ADEPT (NCT01687413) and the
U.K.-based PATHOS (NCT02215265) clinical trials. Con-
currently, the role of TLM in treatment intensification of
HPV-negative and clinicopathological high-risk HPV-pos-
itive oropharyngeal SCC is being investigated in the
U.K.-based COMPARE clinical trial (UKCRN ID 18621).
TLM and transoral robotic surgery (TORS) are mini-
mally invasive surgical techniques that are used to resect
oropharyngeal SCC tumors with the aim of reducing
long-term functional (particularly swallowing) deficit. At
Aintree University Hospitals NHS Foundation Trust, Liv-
erpool, United Kingdom, the largest centralized head and
neck cancer unit in the United Kingdom, it has been rou-
tine practice to offer primary TLM for oropharyngeal
SCC since 2006. The purpose of this study, which consti-
tutes the largest consecutive single center series published
to date, is to present the oncologic and functional out-
comes and our experience of this approach, and to
attempt to define its role in future treatment strategies for
oropharyngeal SCC.
PATIENTS AND METHODS
Patients and setting
This was a retrospective analysis of consecutive
patients with oropharyngeal SCC treated with TLM from
July 2006 to April 2013 at Aintree University Hospitals.
Patients were identified from our regional head and neck
cancer database and cross-referenced with theater records.
The study cohort was restricted to patients with at least
12 months’ follow-up data who were treated with curative
intent using TLM as their primary treatment modality,
combined with postoperative adjuvant therapy when
appropriate.
All clinicopathological, treatment, and oncologic and
functional outcome data for eligible patients were
extracted from hospital records. HPV status was deter-
mined from pathological resection specimens using p16
immunohistochemistry (CINtec Histology, Roche MTM
Laboratories, Basel, Switzerland), followed by high-risk
HPV DNA in situ hybridization (INFORM HPV III Fam-
ily 16 probe B; Ventana Medical Systems, Tucson, AZ),
as previously described.27
Operative technique and adjuvant therapy
Tumor resections were performed under microscopic
control and using an array of equipment, including
bivalved adjustable laryngoscopes (Karl Storz, Tuttlingen,
Germany) as well as a Boyle–Davis tonsil gag or FK-WO
TORS laryngopharyngoscope (Olympus Medical Systems,
Hanoi, Vietnam), to facilitate transoral tumor exposure.
Resection was undertaken using an AcuPulse 40WG C02
laser (Lumenis, Elstree, UK), with the laser beam directed
using an AcuSpot 712 micromanipulator (Lumenis)
attached to the operating microscope. Continuous super-
pulse was the laser setting of choice and power settings
varied from 2 to 10 W depending on the individual case.
In order to maximize appreciation of 3D orientation,
tumors were resected in a transtumoral manner, as popu-
larized by Steiner and Ambrosch,28 and subsequently
pinned and orientated on a corkboard to facilitate accurate
histopathological reporting of surgical resection. Excision
was assessed pathologically by measuring tumor relation-
ship to the deep and mucosal surfaces of the primary
tumor specimen, as well as examining a series of mar-
ginal biopsies taken from the tumor bed and periphery
after perioperative microscopic tumor clearance. A zero-
tolerance policy for involved marginal biopsies was used
and subsequent procedures were undertaken in all cases if
the marginal biopsies were reported as positive to ensure
complete clearance of disease. In such cases, intraopera-
tive frozen sections were utilized as required, particularly
during base of tongue (BOT) resections in which intrao-
perative microscopic evaluation of tumor resection tends
to be more challenging.
Elective or therapeutic neck dissections, the indication
and extent of which was based on standard oncological
criteria, were performed in a standard fashion and in a
single surgical session either preceding or after TLM.
Unless clinically indicated, neck dissection did not
include level I nodes. Additionally, after 2 cases of fatal
hemorrhage (see surgical complications below) it became
our standard practice since September 2010 to ligate the
ipsilateral external carotid artery (ECA), or branches
thereof, cranial to the superior thyroid artery, in order to
mitigate the risk of hemorrhage from the primary tumor
resection site.
Decisions to administer adjuvant therapy were made at
a multidisciplinary level, and were based primarily on
pathology reports of TNM stage and, in particular, the
number of involved ipsilateral and/or contralateral cervi-
cal lymph nodes, the presence of extracapsular spread
(ECS) from nodal metastasis, as well as patient functional
status and comorbidity. In our practice, as previously
stated, there is a zero-tolerance for positive surgical mar-
ginal biopsies. In this context, in keeping with the princi-
ples of TLM, tumor extending to the main section
resection margin is not considered as a positive resection
margin and therefore is not generally taken into account
when considering the advisability or nature of adjuvant
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treatment. Similarly, in our practice, the presence of ECS
did not automatically result in the prescription of postop-
erative CRT. Only when ECS amounting to a soft tissue
deposit29 was present or ECS was associated with other
pathological features of adverse outcome (eg, perineural
and/or vascular invasion, multiple lymph nodes node
exhibiting ECS), was postoperative CRT prescribed for
patients considered fit enough.
For lateralized carcinomas, RT was delivered using
standard 3D conformal RT to a dose of 63 Gy in 30 frac-
tions. For nonlateralized tumors in the earlier part of the
study, RT was delivered using 3D conformal RT with
matched posterior neck electrons, if required, to a dose of
64 Gy in 32 fractions (n 5 20). In the later years of the
study, parotid-sparing intensity-modulated RT (IMRT) to
a dose of 63 Gy in 30 fractions was universally used.
When postoperative CRT was given, the RT dose was 66
Gy in 33 fractions, with concurrent cisplatin administered
at 100 mg/m2 on days 1, 22, and 43 of the RT regimen.
In all cases, the uninvolved lower neck was treated by
matched anterior field (unilateral or bilateral, as appropri-
ate), with central shielding of the larynx, pharynx, upper
esophagus, and spinal cord to a dose of 40.5 Gy in 15
fractions.
Statistical analysis
IBM SPSS version 21 (Armonk, NY) was used for sta-
tistical analyses. Time-to-event analyses using Kaplan–
Meier statistics were used to estimate locoregional con-
trol, overall survival (OS), disease-specific survival
(DSS), and disease-free survival (DFS). All survival/
recurrence times were calculated from the date of treat-
ment completion to the date of occurrence of the event or
the date of last follow-up. In cases in which the follow-
up extended beyond 60 months and no event of interest
had occurred, patients were censored at 60 months.
Tumor recurrence was defined as the emergence of fur-
ther disease at least 6 months after complete TLM
resection.
Log-rank statistics were used to examine the relation-
ship and determine statistical significance (p  .05)
among OS, DSS, DFS and the following variables: AJCC
stage, presence of ECS for those patients who had under-
gone neck dissections, HPV status, and tumor subsite
(tonsil vs BOT). To calculate Hazard Ratios (HR) to
quantify effect size, Cox proportional hazards models
were fitted where appropriate.
Ethical considerations
Data and tissue collection and analysis for this study
was undertaken in accordance with previously granted
ethical approval from North West 5 Research Ethics
Committee (Ref: 10/H1010/37). All patient data were
kept anonymous and encrypted throughout.
RESULTS
Clinicopathological and treatment details
One hundred fifty-three consecutive patients were eligi-
ble for inclusion in this study, 64 and 89 of whom were
treated before and after our ECA ligation strategy, respec-
tively. Mean patient age was 59 years (range, 28–81
years) and 71.9% of patients were men (110 of 153).
Mean duration of follow-up for all surviving patients in
the study cohort was 40 months (range, 12–95 months).
Additional clinicopathological and treatment details are
summarized in Table 1. Of particular note, 66% of
patients (101 of 153) presented with HPV-positive
tumors.
Surgical complications
Major postoperative bleeding occurred in 4 cases
(2.6%) at postoperative days 2, 4, 5, and 8. In 2 cases,
return to the operating theater for endoscopic arrest of
hemorrhage was successful, but, regrettably, in the other
2 cases, hemorrhage proved fatal. It was after these epi-
sodes that we changed our practice, as described above,
to routinely ligate the ECA, or branches thereof, after
neck dissection. Since that change in practice, no episodes
of major hemorrhage have occurred. Otherwise, complica-
tions relating directly to TLM were minor and included
pain at the primary site, bruising to the lips, alveolus, and
tongue. In all cases, such complications were successfully
managed conservatively and resulted in no long-term
adverse sequelae.
TABLE 1. Clinicopathological and treatment details for all patients.
Characteristic No. of patients (%)
Tumor subsite
Tonsil 94 (61.5)
BOT 38 (24.8)
Soft palate 21 (13.7)
HPV status
Positive 101 (66.0)
Negative 52 (44.0)
AJCC stage
I 13 (8.5)
II 16 (10.5)
III 38 (24.8)
IV 86 (56.2)
T classification
T1 42 (27.5)
T2 74 (48.4)
T3 37 (24.2)
N classification*
N0 31 (20.3)
N1 27 (17.6)
N2 94 (61.4)
N3 1 (0.7)
Neck dissection
Yes 123 (80.4)
No 30 (19.6)
ECS†
Yes 50 (40.7)
No 73 (59.3)
Adjuvant treatment
None 24 (15.7)
RT alone 121 (79.1)
CRT 8 (5.2)
Abbreviations: BOT, base of tongue; HPV, human papillomavirus; AJCC, American Joint Com-
mittee on Cancer; ECS, extracapsular spread; RT, radiotherapy; CRT, chemoradiotherapy.
* In cases in which no neck dissection was undertaken, the cN is detailed rather than the pN.
† Percentages quoted for ECS are with respect to the number of patients who underwent
neck dissections and consequently for which a pN status and pathology report was available.
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Oncologic outcomes
Sixteen patients (10.4%) suffered disease recurrence
during the study period at a mean time of 16 months
(range, 6–36 months) after completion of initial treatment.
Of these cases, recurrence occurred at more than 1 site in
4 patients. Patterns of recurrence with respect to primary
disease stage are illustrated in Table 2. Twelve patients
(7.8%) suffered local and/or regional recurrence, resulting
in a 3-year locoregional control estimate of 89.6% (see
Figure 1).
One hundred twenty-six patients (82.4%) were living
without evidence of disease recurrence, or further recur-
rence in cases of successful salvage, at most recent
follow-up or at completion of 60 months’ follow-up.
Fourteen patients (9.2%) died of causes related to their
oropharyngeal SCC, 11 (7.2%) died of intercurrent dis-
eases, and 2 (1.3%) died of second primary tumors.
Three-year OS, DSS, and DFS were 84.5%, 91.7%, and
78.2%, respectively (see Figure 2).
HPV status was the only variable observed to impact
significantly on any survival parameter with no statisti-
cally significant influence noted for AJCC stage, ECS, or
tumor subsite (Table 3). Specifically, HPV positivity was
associated with favorable OS (HR, 0.286; 95% CI, 0.128–
TABLE 2. Patterns of recurrence with respect to primary disease
American Joint Committee on Cancer stage.
AJCC stage Local Regional Distant
I 2 1 0
II 1 0 0
III 4 4 1
IV 5 3 3
Abbreviation: AJCC, American Joint Committee on Cancer.
FIGURE 1. Kaplan–Meier plot of locoregional disease control for
entire study cohort (3-year estimate 89.6%). [Color figure can be
viewed in the online issue, which is available at wileyonlineli-
brary.com.]
FIGURE 2. Kaplan–Meier plots of overall survival (A), disease-
specific survival (B), and disease-free survival (C) for entire study
cohort. Three-year estimates of which were 84.5%, 91.7%, and
78.2%, respectively. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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0.640) and DFS (HR, 0.234; 95% CI, 0.108–0.510), as
depicted in Figure 3.
Within the HPV-positive subgroup, again, no significant
relationships were observed between any survival parame-
ter and either AJCC stage or ECS.
Functional outcomes and bed occupancy
All patients were assessed with regard to their swallow-
ing function by a dedicated speech and language therapist
during their postoperative inpatient stay. In no cases were
gastrostomy (G-tubes) inserted pretreatment. One hundred
forty-nine patients (97.4%) were swallowing normally on
discharge from the hospital, with the remaining 4 patients
discharged on G-tube feeding. Of those requiring G-tube
feeding on discharge, in 2 cases, the G-tubes were
removed at 2 and 4 months after discharge subsequent to
regained swallowing function, whereas in 2 cases, G-
tubes remain in situ. As such, the 1-year G-tube depend-
ency rate for our patient group was 1.3%.
As was more common in our early experience, 12
patients underwent elective tracheostomy, performed at
the time of TLM. In 1 case, this was undertaken to pro-
tect the airway after exposure of the internal carotid
artery during primary tumor resection, whereas, in the
remainder of cases, the decision to perform a tracheos-
tomy was taken preoperatively, in light of the presenting
tumor volume and anticipated airway/aspiration-related
complications. All patients who underwent tracheostomy
were decannulated successfully in the postoperative
period at a mean of 10 days (range, 4–15 days). Since
adopting our ECA ligation strategy, only 1 patient had an
elective tracheostomy with respect to anticipated postop-
erative aspiration/airway compromise.
For the whole cohort, the mean duration of postopera-
tive inpatient stay after TLM was 8 days (range, 0–41
days). Two patients remained in the hospital for pro-
tracted periods (24 and 27 days) owing to swallowing
issues, whereas in 4 cases prolonged admission was
attributable to comorbidities and social issues. Otherwise,
all patients were discharged within 10 days of surgery.
However, after commencement of our ECA ligation strat-
egy, the inpatient stay was reduced to a mean of 5 days
(range, 1–27 days) as protracted monitoring for hemor-
rhage was no longer required. Furthermore, when adjusted
to account only for reasons attributable to oropharyngeal
SCC treatment (ie, excluding, for example, social reasons
for delayed discharge), the inpatient stay was reduced to
a mean of 3 days.
DISCUSSION
The present study, which represents the largest single-
center experience of the use of TLM as a primary treat-
ment modality for oropharyngeal SCC, supports the
notion that primary TLM is an oncologically sound thera-
peutic option for oropharyngeal SCC. For our study
cohort as a whole, 81.0% of which comprised stage III or
IV disease, we observed a 3-year locoregional control
rate of 89.6% and, respective, 3-year OS, DSS, and DFS
rates of 84.5%, 91.7%, and 78.2%, which, although chal-
lenging to compare with the oncologic outcomes from
previous contemporary surgical series owing to varying
TABLE 3. Univariate analysis of the impact of different variables on
survival outcome measures as assessed using log-rank tests.
Variables OS DSS DFS
AJCC stage p5 .385 p5 .488 p5 .079
ECS p5 .271 p5 .431 p5 .271
HPV status p5 .001* p5 .304 p < .0001*
Tumor subsite† p5 .578 p5 .345 p5 .697
Abbreviations: AJCC, American Joint Committee on Cancer; ECS, extracapsular spread; HPV,
human papillomavirus.
* These figures indicate statistical significance (p < .05).
† Analysis for tumor subsite done for only the two most frequently implicated subsites (tonsil
and base of tongue), with the small number of soft palate cases (n5 21) excluded.
FIGURE 3. Kaplan–Meier plots of overall survival (A) and disease-
free survival (B) dichotomized by human papillomavirus (HPV)-16
status. HPV-16 positivity conferred favorable overall survival (p 5
.001) and disease-free survival (p < .0001). [Color figure can be
viewed in the online issue, which is available at wileyonlineli-
brary.com.]
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distributions of disease stage, HPV status, and adjuvant
therapy strategy, seem broadly consistent. In the earliest
published report of primary TLM to treat oropharyngeal
SCC, Steiner et al30 noted a 5-year local control estimate
of 85% and DFS and OS estimates of 73% and 52%,
respectively, for a small cohort (n 5 48) of patients with
BOT SCC, whereas a recent update of these data, includ-
ing an additional 82 patients with more mature follow-up,
demonstrated respective 5-year local control, DFS, and
OS rates of 84%, 69%, and 59%.31 Similar oncological
outcomes have been reported in three US single-center
series,13,32,33 with particularly propitious results reported
in a recent appraisal of 80 patients with advanced oropha-
ryngeal SCC, albeit predominantly low T classification,
from the Mayo Clinic Arizona: respective 3-year locore-
gional control, DFS, and OS estimates were 98.6%,
91.1%, and 93.7%, respectively.32 Perhaps most notably,
however, in the largest TLM oropharyngeal SCC study to
date – a multicenter series that amalgamated data for 204
patients followed for a minimum of 2 years from the 3
aforementioned U.S. centers – respective 2-year and 5-
year estimates of OS, DSS, and DFS were reported as fol-
lows: 89% and 78%, 91% and 84%, and 85% and 74%.9
Furthermore, oncologic outcomes reported for oropharyn-
geal SCC treated with TORS, which follows broadly the
same surgical and oncologic principals as TLM, have also
been congruous.34
Importantly, oncologic results achieved with such mini-
mally invasive surgical approaches are at least compara-
ble to those reported for primary nonsurgical regimens.
Again, although comparison is hindered by differences
between studies in disease stage and reporting of positiv-
ity for HPV status, those that are comparable, at least in
terms of disease stage and which have been conducted
during the era of high prevalence HPV-driven disease,
reveal very similar oncologic outcomes. In a CRT study
of 71 patients all with AJCC stage III/IVa oropharyngeal
SCC, and containing 32% T3 and T4 cases, Huang et al12
reported 3-year OS and locoregional control rates of 83%
and 90%, respectively (salvage surgery included). In con-
trast, 3-year OS and DFS estimates in the oropharyngeal
SCC subgroup (n 5 433; 100% AJCC stage III/IVa) of
the Radiation Therapy Oncology Group 0129 study com-
paring accelerated-fractionation RT and standard-
fractionation RT as part of primary CRT regimens were
82.4% and 73.7% for HPV-positive patients and 57.1%
and 43.4% in HPV-negative patients, respectively.4 More
recently, Setton et al35 reported a 3-year OS of 84.9%
and respective local and regional failure rates of 5.4%
and 5.6% in the largest primary nonsurgical oropharyn-
geal SCC series to date, which included 442 patients
(94% AJCC stage III/IV) all treated with IMRT, of which
88% received concurrent chemotherapy. Proponents of
primary CRT would argue for the systemic benefits of
CRT over surgery or RT alone in reducing recurrences
and deaths from distant metastases, as has been reported
in earlier clinical trials in SCCHN more generally.36 It is,
however, likely that some degree of discrepancy existed
among patient groups in these trials regarding their pre-
treatment distant metastatic status in view of the fact that
whole body functional imaging techniques were not avail-
able for routine use, thereby introducing bias in compar-
ing treatment groups.36 Furthermore, in the present study,
in which only 8 patients (5.2%) received adjuvant CRT,
only 2.6% of all patients suffered distant recurrences,
whereas 5.9% did so in the TLM multicenter series, in
which 16.2% were treated with adjuvant CRT,9 outcomes
comparable to the primary CRT series.
Functional outcome, most notably posttreatment swal-
lowing function, is also crucial when considering treat-
ment options for patients with oropharyngeal SCC,
particularly given the apparently similar oncologic results
achieved with competing therapeutic approaches. Indeed,
the belief that “organ-preserving” primary nonsurgical
treatment regimens offered favorable functional outcomes
in comparison with traditional en bloc surgical
approaches was a principal motivating factor in the wide-
spread shift toward primary nonsurgical management of
SCCHN, oropharyngeal SCC included.8,37 Although there
is no doubt that previous major open surgical approaches
carried significant risks of posttreatment morbidity and
mortality, it is now apparent that use of chemotherapy in
conjunction with RT to the head and neck is also associ-
ated with high rates of acute and late toxicity in the
majority of patients, particularly with respect to degluti-
tion, over and above those seen with RT alone.11,15–25
Although, when assessing swallowing function there is no
universally recognized single method of measuring out-
come,38 it is apparent that primary CRT regimes often
necessitate protracted or permanent nonoral feeding, with
high rates of G-tube dependency reported – a crude but
objective measure of swallowing outcome. Indeed, in an
analysis of swallowing outcomes after definitive CRT for
advanced oropharyngeal SCC, Shiley et al21 observed a
1-year G-tube dependency rate of 31%, whereas Patterson
et al22 noted a similarly high rate in a prospective longi-
tudinal study of swallowing outcomes in a cohort of
patients with advanced SCCHN treated with CRT, a sig-
nificant proportion of whom were treated for oropharyn-
geal SCC (53%). Although the use of IMRT certainly
seems to have improved the situation, for example, a
recent large-scale U.S. multi-institution pooled analysis
demonstrated a 1-year dependence of 8.6% in those
treated with concurrent chemotherapy and IMRT (n 5
1238),39 results from our experience with TLM remain
favorable by comparison (1-year G-tube dependency of
1.3%). Moreover, similarly low rates of G-tube depend-
ency have been reported in the other aforementioned
TLM series.13,32,33 Unfortunately, although such favorable
G-tube dependency rates are compelling, our series, and
indeed the previous TLM series, lack more comprehen-
sive data regarding swallowing function pretreatment and
posttreatment, and, more importantly, lack a direct com-
parator group treated nonsurgically to allow for a more
robust analysis of swallowing outcomes. To this end,
there is an ongoing effort in our department to incorpo-
rate routine measurement of an array of both subjective
and objective swallowing evaluations as part of our stand-
ard minimum dataset. Nonetheless, a number of recent
direct comparator studies specifically examining swallow-
ing outcomes have also demonstrated advantageous swal-
lowing outcomes in those treated with minimally invasive
surgery compared to a primary nonsurgical approach.40,41
In a nonrandomized, case-matched study of patients
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treated for advanced oropharyngeal SCC with either CRT
or TLM, O’Hara et al40 observed significantly better
swallowing scores for the TLM cohort at 3 months after
treatment, as assessed with patient-reported outcomes
using the MD Anderson Dysphagia Inventory, clinician-
rated dietary texture restrictions using the Normalcy of
Diet scale, and objective swallow performance using the
timed Water Swallow Test. Furthermore, all patients in
the TLM cohort were able to complete the Water Swal-
low Test, whereas, in the CRT group, 5 patients were
unable to do so owing to overt aspiration.40 Similarly, in
a recent prospective longitudinal study examining patient-
rated swallowing function in patients with advanced oro-
pharyngeal SCC treated either with TORS or CRT, MD
Anderson Dysphagia Inventory scores were significantly
more favorable for those treated with TORS at 6-month
and 12-month follow-up.41
This question of survivorship becomes yet more perti-
nent when considering the ever-increasingly prevalence of
HPV-positive oropharyngeal SCC. HPV-driven disease is
associated with excellent long-term oncologic outcomes
irrespective of treatment modality used,1,4–8,42 something
also observed incontrovertibly in our study group, with
HPV positivity conferring a 76.6% reduction in risk of
death and/or disease recurrence. Additionally, HPV-
driven disease tends to affect younger and generally med-
ically fitter patients without conventional risk factors,
who are thus likely to experience the functional ramifica-
tions of their treatment long term. Consequently, it has
been argued that treatment strategies for such patients
should be deintensified in order to optimize the therapeu-
tic index,1,8 but uncertainty remains regarding the opti-
mum means by which to accomplish this. Upfront
minimally invasive endoscopic surgical techniques, how-
ever, lend themselves well to this strategy: primary
tumors can be resected with little, if any, functional defi-
cit, and although the functional advantage may be obvi-
ated to a degree with administration of adjuvant therapy,
this can be tailored based on the full pathological and
staging assessment made available by surgical resection,
notionally enabling reduced doses of adjuvant RT, poten-
tial reduction in RT fields, and rationalization of chemo-
therapy use. The current evidence for use of CRT in the
postoperative setting comes from 2 seminal trials from
2004, which demonstrated significant improvements in
survival and locoregional control for patients with
advanced SCCHN treated with postoperative CRT com-
pared with postoperative RT (PORT) only.15,18 A subse-
quent pooled analysis of these studies demonstrated that
postoperative CRT significantly improved survival in
patients with microscopically involved surgical resection
margins and/or ECS, and, on this basis, postoperative
CRT became the standard of care for the adjuvant treat-
ment of patients with head and neck cancer with these
high-risk pathological features.16 These studies, however,
included all subsites of SCCHN and, given the chronol-
ogy of patient recruitment to these trials, during which
time the incidence of HPV-positive oropharyngeal SCC
was in the region of 35.3% (95% CI, 27.8–43.5%),2 it is
likely that HPV-positive oropharyngeal SCC was not
well-represented. Accounting for these factors, only 28 to
44 and 50 to 76 patients, respectively, in these trials,
would have had HPV-positive oropharyngeal SCC, and,
as such, the apparent benefit of postoperative CRT may
not extrapolate to the postoperative management of HPV-
positive oropharyngeal SCC. Indeed, results from the
present study lend credence to this notion: in our HPV-
prevalent patient group (66.0% of our cases) excellent
oncologic outcomes were achieved despite the over-
whelming majority of our study cohort (94.8%) being
treated without the use of postoperative CRT even in the
presence of ECS in a considerable proportion of patients
(44.4% of those who underwent neck dissections),
whereas ECS was not predictive of oncologic outcome.
Congruous results have also been observed in previous
TLM series with similarly high rates of HPV positivity in
which only a minority of patients were treated with adju-
vant CRT,9,13,30–33 albeit a greater proportion than in the
present series. Furthermore, in the U.S. multicenter TLM
study, again, ECS was not prognostic and no significant
survival advantage was observed in the subgroup of
patients receiving postoperative CRT compared with
those who received PORT.9 These findings were corrobo-
rated in a follow-up study by the same research group
using multivariate and matched analyses controlling for
conventional high-risk pathological criteria in a patient
cohort with HPV-positive disease exclusively.43 Although
such findings underpin the shift toward reduced intensity
adjuvant treatment strategies, it is hoped that the U.S.-
based ADEPT and Eastern Cooperative Oncology Group
3311 randomized controlled trials (RCTs), as well as the
U.K.-based RCT, PATHOS trial designed to truly, and
more definitively, address these issues will help inform
future management strategies for surgically treated HPV-
positive oropharyngeal SCC.
CONCLUSIONS
Outcomes from this study, in conjunction with the lim-
ited volume of previously published data, attest primary
TLM – in combination with PORT when indicated – for
the treatment of intermediate stage oropharyngeal SCC to
be at least as oncologically effective as current nonsurgi-
cal treatment regimes, while conferring discernible func-
tional advantages with respect to swallowing. Such
findings substantiate TLM as a highly effective primary
treatment option for the management of selected cases of
oropharyngeal SCC. Our data also lend support to the
notion of treatment deescalation for HPV-positive oropha-
ryngeal SCC, and, once again, invites scrutiny of the
need for postoperative CRT for pathologically high-risk
cases of HPV-positive oropharyngeal SCC. The authors
accept, however, that the conclusions that can be drawn
from this study are limited because of its retrospective
nature and the lack of robust experimental design,
namely, the absence of comparator groups. Nonetheless,
we believe that the evidence presented is sufficient to
consider primary TLM as a putative standard of care and
validates the necessity to perform appropriately powered
RCTs to identify the optimal treatment strategies for both
clinicopathological low-risk HPV-positive as well as clin-
icopathological high-risk HPV-positive and HPV-negative
oropharyngeal SCC subgroups.
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